StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) income statement

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.28+0.10 (+2.39%)

Close on Nov 18, 2026Market cap $106.09MP/E –Yield –

Lexaria Bioscience Corp. income statement

Ratios

Latest available, balances at May 31, 2026

Profitability, TTM

Gross margin
100.0%
Operating margin
-3973.2%
Net margin
-3985.6%
Return on equity, FY2025
-215.9%

Financial strength

Current ratio
10.60
Debt to equity
–
Debt to assets
–
Cash to current liabilities
912.9%

Valuation

P/E ratio
–
Price to sales
546.86
Price to book
22.39
Dividend yield
–

See a number that looks wrong?